FTC looks into ads for genetic tests

The Federal Trade Commission has opened an investigation into the possible deceptive advertising and marketing of DTC genetic tests, according to The New York Times

Matthew Arnold

July 14, 2008

8:06 pm

The Federal Trade Commission has opened an investigation into the possible deceptive advertising and marketing of DTC genetic tests, according to The New York Times, which cited an FTC official speaking at a June 12 meeting convened by Sen. Gordon Smith (R-OR).

Earlier in June, the AMA’s House of Delegates adopted a resolution calling for more regulation of advertising by the industry, while California sent cease and desist letters to 13 companies that offer consumer genetic tests, demanding they stop testing until they can prove that their labs are licensed and that the tests were ordered by physicians, not patients.

From the August 01, 2008 Issue of MM+M - Medical Marketing and Media

From Our Partners

Mapping the identity experience in digital health communications

Partner Content

Mapping the identity experience in digital health communications

How IX offers greater nuance in engaging with audiences.

The state of DE&I: Moving the needle from commitment to progress

Partner Content

The state of DE&I: Moving the needle from commitment to progress

Employees and consumers alike expect companies to take meaningful steps toward creating a more equitable and inclusive future. As shown by the findings from MM+M’s 2022 Diversity Survey, conducted in partnership with IPG Health, progress has been made but we still have a long way to go in the healthcare industry.

How to keep digital pharma marketing relevant in the times of global crises

Partner Content

How to keep digital pharma marketing relevant in the times of global crises

Nataliya Andreychuk, CEO of Viseven, discusses digital marketing trends and more during her chat with Marc Iskowitz, editor-at-large, MM+M.

Why marketers must make the switch to privacy-safe real-world data for targeting

Partner Content

Why marketers must make the switch to privacy-safe real-world data for targeting

Developing more precise and brand-exclusive patient segments with higher audience quality.